MULTINOMIAL PHASE II CANCER TRIALS INCORPORATING RESPONSE AND EARLY PROGRESSION

DOI10.1081/BIP-100101181MaRDI QIDQ4512728zbMATH OpenOpenAlexWikidataFDO

Authors Benny Zee, David Melnychuk, Janet Dancey, Elizabeth Eisenhauer

Publication date 27 February 2001

Published in Journal of Biopharmaceutical Statistics (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1081/bip-100101181

zbMATH Keywords

missing dataoncologyclinical trialmultiple-stage stopping rulemultivariate endpoint

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical analysis (62L10)

Recommendations

• Randomized phase II cancer clinical trials
• Optimal adaptive two-stage designs for phase II cancer clinical trials
• Improving the flexibility and efficiency of phase II designs for oncology trials
• Adaptive Two-Stage Designs for Single-Arm Phase IIA Cancer Clinical Trials
• Two-stage design for phase II oncology trials with relaxed futility stopping

Cites work

• A Bayesian Approach to the Design of Phase II Clinical Trials
• Bivariate Sequential Designs for Phase II Trials
• Designs for Group Sequential Phase II Clinical Trials
• Designs for Phase II Trials Allowing for a Trade-Off between Response and Toxicity
• One-Sample Multiple Testing Procedure for Phase II Clinical Trials
• Practical Bayesian Guidelines for Phase IIB Clinical Trials

Cited in

(7)

• Evaluation of treatment effect with paired failure times in a single-arm phase II trial in oncology
• Boundary crossing random walks, clinical trials, and multinomial sequential estimation
• Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control
• Randomized phase II cancer clinical trials
• Design efficiency in dose finding studies
• Testing statistical hypotheses on stochastic ordering of discrete distributions
• A multistate model for early decision-making in oncology

This page was built for publication: MULTINOMIAL PHASE II CANCER TRIALS INCORPORATING RESPONSE AND EARLY PROGRESSION

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q4512728)